VEGFR |
Bevacizumab |
Monoclonal antibody against VEGFR |
Active in glioblastoma, activity in newly diagnosed glioblastoma being prospectively evaluated in RTOG 08-25 |
VEGFR |
Cediranib |
pan-VEGF receptor inhibitor |
No improvement in survival in combination with lomustine over lomustine alone |
MET, VEGFR-2 |
XL-184 |
pan-tyrosine kinase inhibitor |
Phase II study ongoing |
EGFR |
Gefitinib, erlotinib |
Receptor tyrosine kinase inhibitors |
Gefitinib+RT not superior to RT alone, erlotinib+RT+temozolomide being evaluated |
EGFR |
Rindopepimut |
Vaccine to EGFRvIII |
Active in glioblastoma, being studied in ACT III study |
PARP-1 |
Iniparnib |
Poly(ADP-ribose) polymerase-1 inhibitor |
Reversed temozolomide resistance in a murine xenograft |
Integrin alpha-v/beta-3 and alpha-v/beta-5 |
Cilengitide |
Inhibits alpha-v integrin signaling |
Phase III study comparing cilengitide to conventional chemoradiation versus conventional treatment alone ongoing |
Notch pathway |
GSI RO4929097 |
Gamma secretase inhibitor |
Phase II study ongoing |